Table 3.
Hazard ratios for microRNA classifiers by cancer type and outcome in test cohorts*
| First author (reference) | Cancer type | Outcome | Test set sample size | Prognostic miR(s)† | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Variables adjusted for in test set |
| Zhi (58)‡ | Astrocytoma | OS | 40 | 21 | 1.84 (1.05 to 3.22) | 1.88 (1.07 to 3.31) | Sex, age, WHO grade |
| Zhi (58) | Astrocytoma | OS | 40 | 106a | 1.72 (0.99 to 2.99) | 1.63 (0.90 to 2.95) | Sex, age, WHO grade |
| Zhi (58) | Astrocytoma | OS | 40 | 181b | 1.87 (1.07 to 3.26) | 1.86 (1.03 to 3.37) | Sex, age, WHO grade |
| Foekens (26) | Breast | M | 147 | 57, 128a, 210, 516-3p | NR | 5.4 (2.4 to 11.8) | Age, menopausal status |
| Schetter (47) | Colon | OS | 103 | 21 | 2.4 (1.4 to 3.9) | 2.4 (1.4 to 4.1) | Stage |
| Guo (28)‡ | Esophageal | OS | 22 | 103, 107 | 3.62 (1.53 to 8.57) | 2.60 (1.01 to 6.70) | Stage, N |
| Ogawa (41) | Esophageal | OS | 19 | 129 | 5.78 (1.49 to 22.4) | NR | NR |
| Mathe (37)‡ | Esophageal | OS | 69 | 223 | 2.33 (1.03 to 5.26) | 4.00 (1.45 to 11.1) | Study center, neoadjuvant therapy, N |
| Mathe (37) | Esophageal | OS | 69 | 21 | 1.17 (0.54 to 2.51) | NR | NR |
| Budhu (16)‡ | Hepatocellular | OS | 110 | 20 miR composite | 2.1 (1.2 to 3.7) | 2.1 (1.2 to 3.6) | Stage, tumor encapsulation |
| Budhu (16) | Hepatocellular | M | 110 | 20 miR composite | 1.85§ | NR | NR |
| Cairo (17) | Hepatocellular | OS | 46 | 371–3, 100, let-7a-2, 125b-1 | 6.74 (2.02 to 22.5) | NR | NR |
| Calin–Visone (18,52)‖ | Leukemia | P | 16 | 181 | 2.00§ | NR | NR |
| Garzon (27) | Leukemia | OS | 60 | 191 | NR | 2.35 (1.18 to 4.75) | Allelic ratio, WBC |
| Garzon (27) | Leukemia | OS | 60 | 199 | NR | 2.81 (0.96 to 8.23) | Allelic ratio, WBC |
| Garzon (27) | Leukemia | R | 60 | 191 | NR | 2.29 (1.15 to 4.55) | Allelic ratio, WBC |
| Garzon (27) | Leukemia | R | 60 | 199 | NR | 2.57 (0.93 to 3.51) | Allelic ratio, WBC |
| Marcucci (36) | Leukemia | R | 55 | 9 miR composite | 1.99 (1.07 to 3.69) | Age, WBC, cytogenetics | |
| Yanaihara (53) | Lung | OS | 32 | let-7a | 2.22 (0.91 to 5.71) | 2.97 (1.07 to 8.23) | Age, sex, stage, smoking |
| Yanaihara (53) | Lung | OS | 32 | 155 | 2.52 (1.10 to 7.45) | 3.77 (1.32 to 10.6) | Age, sex, stage, smoking |
| Yu (55) | Lung | R | 62 | 137, 372, 182, 221, let-7a | NR | 2.86 (1.20 to 6.82) | Stage, age |
| Yu (55) | Lung | OS | 62 | 137, 372, 182, 221, let-7a | NR | 3.65 (1.29 to 10.4) | Stage, age |
| Caramuta (19) | Melanoma | OS | 16 | 191 | 8.82 (2.00 to 38.8) | NR | NR |
| Caramuta (19) | Melanoma | OS | 16 | 193b | 8.43 (1.92 to 37.1) | NR | NR |
| Pass (42) | Mesothelioma | R | 92 | 29c | 2.31§ | NR | Stage, sex, N |
| Pass (42) | Mesothelioma | OS | 92 | 29c | 2.39 (1.26 to 3.11) | NR | NR |
| Bray (14) | Neuroblastoma | OS | 48 | 15 miR composite | 4.31 (1.66 to 11.2) | NR | NR |
| Bray (14) | Neuroblastoma | R | 48 | 15 miR composite | 4.50 (1.74 to 11.7) | NR | NR |
| Bray–Buckley (14,15)‖ | Neuroblastoma | OS | 37 | 15 miR composite | 2.26 (1.07 to 4.78) | NR | NR |
| Bray–Buckley (14,15)‖ | Neuroblastoma | R | 37 | 15 miR composite | 2.22 (1.04 to 4.75) | NR | NR |
| Schulte (48) | Neuroblastoma | R | 19 | 42 miR composite | 13.8 (2.62 to 72.4) | NR | NR |
| Schulte (48) | Neuroblastoma | OS | 19 | 42 miR composite | 19.7 (2.99 to 130) | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 20b | 1.39§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 130b | 1.15§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 454 | 1.15§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 99b | 0.96§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 181c | 0.98§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | let-7 | 1.06§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 532 | 0.99§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 362 | 1.00§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 363 | 1.15§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 625 | 1.11§ | NR | NR |
| Di Lisio (23) | NHL | OS | 54 | 660 | 1.07§ | NR | NR |
| Yang (54) | Ovarian | R | 62 | let-7i | 2.47 (1.39 to 4.38) | NR | NR |
| Schaefer (45) | Prostate | R | 79 | 96 | NR | 3.55 (0.95 to 13.3) | Grade |
*
CI = confidence interval; HR = hazard ratio; MiR = microRNA; N = node stage; M = metastasis; NHL = non-Hodgkin lymphoma; NR = Not reported or calculations not possible for deriving metric; OS = overall survival; P = progression; R = recurrence; WBC= white blood cell count; WHO = World Health Organization.
†
Classifiers comprising more than five miRs are presented in Supplementary Table 2 (available online).
‡
These studies combined training and testing cohorts and the resulting data are presented.
§
CI not given and/or unable to be imputed.
‖
Separate study providing external validation to parent study.